Articles by H Kantarjian (3)

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

A Quintas Cardama, H Kantarjian, D Jones, J Shan, G Borthakur, D Thomas, S Kornblau, S O'Brien and J. Cortes

Blood 113 ( 25 ): 6315 - 6321 , 2009

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

H Kantarjian, J Cortes, D. W Kim, P Dorlhiac Llacer, R Pasquini, J DiPersio, M. C Muller, J. P Radich, H. J Khoury, N Khoroshko, M. B Bradley Garelik, C Zhu and M. S. Tallman

Blood 113 ( 25 ): 6322 - 6329 , 2009

Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

W Ma, H Kantarjian, B Bekele, A. C Donahue, X Zhang, Z. J Zhang, S O`Brien, E Estey, Z Estrov, J Cortes, M Keating, F Giles and M. Albitar

Clinical Cancer Research 15 ( 11 ): 3820 - 3826 , 2009

Do you have a suggestion for journals

Suggest Journal